NPPA fixed Ceiling price of 6 scheduled formulations: November 2025

Last Updated on January 13, 2026 by The Health Master

NPPA

Download NPPA notification No. S.O. 5018(E) dt 04-11-2025, the link is given below: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 6 scheduled formulations vide S.O. 5018(E) dt 04-11-2025, based on the decision of 138th Authority meeting dated 30.10.2025.

The notification states as follows:

In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority), S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the The National Pharmaceutical Pricing Authority hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

The table is given below

Sl. No.	Medicines	Dosage form and strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1	Riboflavin	Tablet 10mg	1 Tablet	1.11
2	Peritoneal dialysis solution	As licensed	1 ML	0.22
3	Ethyl alcohol (Denatured)	Solution 70%	1 ML	0.40
4	Human normal immunoglobulin	Solution for infusion (16.5%)	1 ML	478.57
5	Human normal immunoglobulin	Solution for infusion (10%)	1 ML	206.53
6	Human normal immunoglobulin	Solution for infusion (5%)	1 ML	148.60

Note:

(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus Goods and Services Tax as applicable, if any), shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

• IP 2026 released: Salient Features
  January 7, 2026
• Drug alert: 205 drug samples declared as NSQ in November 2025
  December 25, 2025
• FDA Haryana is Redefining Drug Safety and MSMEs Growth
  December 17, 2025
• 10th edition of IP for standards of drugs in India
  December 9, 2025
• QR Code mandatory at every Medical Store for ADR reporting
  November 26, 2025
• Landmark Seminar by FDA Haryana on Spurious drugs and NDPS Misuse
  November 25, 2025